Abstract. It is known that an epidermal growth factor receptor (EGFR) gene mutation(s) is present in a percentage of nonsmall cell lung cancers (NSCLCs). Gefitinib, an inhibitor of the tyrosine kinase activity of EGFR, is effective on most of them. The EGFR mutation status alone cannot fully predict the response to gefitinib and the prognosis for the patients. We hypothesized that information on the expression levels of phosphorylated-EGFR and -Akt, and E-cadherin, alone or in combination with information on the EGFR mutation, may refine our ability of prediction. We investigated 24 NSCLCs that had recurred after surgery and were treated with gefitinib.
Introduction
Gefitinib (ZD1839, Iressa, AstraZeneca, Wilmington, DE) is a therapeutic reagent for non-small cell lung cancers (NSCLCs). It shows dramatic anti-tumor effects in some patients, but has no effect in others (1) . The presence of an epidermal growth factor receptor (EGFR) gene mutation(s) (hereafter EGFR mutation) associates significantly with the gefitinib responsiveness (2, 3) and serves as a marker in the choice of therapeutic regimens (4) . Some tumors with an EGFR mutation do not respond to gefitinib therapy while those with wild-type gene do (5-7), so additional markers are required to more precisely select tumors that respond to gefitinib.
EGFR transmits signals that direct cell proliferation and survival. The wild-type EGFR preferentially transmits cell proliferation signals through Erk, while the mutant EGFR preferentially transmits cell survival signals through Akt or STAT (8) . Gefitinib effectively inhibits the latter (2) . This is why gefitinib selectively elicits an apoptotic response in cells with an EGFR mutation, thereby producing its clinical response (8) . We hypothesized that molecules that interact with EGFR or are located downstream in the pathway modify the tumor cell response to gefitinib and therefore serve as markers that may help to more precisely predict their responsiveness to gefitinib.
In this study, three molecules were tested for their predictive ability, p-EGFR (phosphorylated at Tyr1173: pTyr1173), p-Akt (phosphorylated at Ser473: pSer473) and E-cadherin, in addition to the EGFR mutation status. p-EGFR(pTyr1173) transmits a signal that directs cell proliferation (9), p-Akt(pSer473) mediates signals that direct cell survival (10) and E-cadherin has been shown to interact with EGFR by modifying its activity (11) . We investigated the expressions of these three molecules by immunohistochemistry 
Materials and methods
Patients. This study was approved by the Tsuboi Cancer Center Hospital ethics board. After the written informed consent was obtained, we enrolled 24 Japanese patients who had suffered from lung cancers which were resected between 1996 and 2004 (Tsuboi Cancer Center Hospital, Fukushima, Japan) and then had recurred. The patient characteristics are summarized in Table I DNA extraction and mutation analysis. DNA was extracted from the paraffin-embedded tumor tissue (13) (14) (15) . EGFR mutations were detected using the peptide nucleic acidlocked nucleic acid (PNA-LNA) polymerase chain reaction (PCR) clamp. This method, which has been described in detail elsewhere, is a rapid and sensitive detection system for EGFR gene mutations and can detect point mutations G719C, G719S, L858R and L861Q and deletions in exon 19 in the presence of a 100-to 1.000-fold background of wild-type EGFR (4, 6, 16) .
Immunohistochemistry and scoring. Formalin-fixed, paraffinembedded tumor tissue was tested for immunoreactivity to p-EGFR, p-Akt and E-cadherin. The primary antibodies used were: anti-p-EGFR that detects EGFR protein phosphorylated at Tyr1173 (Cell Signaling Technology Beverly, MA), antip-Akt that detects Akt protein phosphorylated at Ser473 (Cell Signaling Technology) and anti-E-cadherin (BD Biosciences, Beverly, MA). Tissue sections cut at a thickness of 5 μm were placed on glass slides, deparaffinized and then rehydrated. Antigen was quantified using the following procedure. The slides were incubated in citrate buffer in a steamer for 15 min. Endogenous peroxidase activity was quenched by incubating the slides in 3% hydrogen peroxide for 5 min and non-specific background staining was blocked by incubation in a protein block for 5 min. Sections were then reacted with primary antibody dilutions (p-EGFR a 1/400 dilution at 37˚C for 15 min, p-Akt a 1/50 dilution at 4˚C for 16 h and E-cadherin a 1/100 dilution at 37˚C for 32 min). The bound antibody was detected by biotinylated secondary antibody and visualized using diaminobenzidine (DAB) chromogen. Sections were then counterstained with Mayer's hematoxylin and mounted using the resinous mounting medium. The p-EGFR and p-Akt stainings were scored by their cytoplasmic and nuclear staining, while E-cadherin staining was scored by its membrane staining (17) (18) (19) , all without the knowledge of clinical or laboratory information. The cytoplasmic and nuclear staining of the entire tumor was scored as follows: First, 500 randomly selected tumor cells (50 cells per randomly chosen microscopic field at x40 magnification) were scored as 0 (no staining), 1 (mild), 2 (moderate) or 3 (strong staining). Second, for p-EGFR, the most intense staining observed in >1% of the cells was the staining score for the tumor. For p-Akt, the mode of the cytoplasmic or nuclear staining score, whichever was greater, was the staining score for the tumor. Tumors with staining scores of 0 or 1 were ranked negative and scores of 2 or 3 were ranked positive. The membrane staining of the entire tumor was scored as 0 when no tumor cells were stained, 1 when <10% Table I . Patient characteristics. 
showed weak membrane staining, 2 (weakly positive) when >10% showed complete membrane staining although with weak to moderate intensity and 3 (strongly positive) when >10% had complete and strong membrane staining. Entire tumors with staining scores of 0 or 1 were considered negative while those scored as 2 or 3 were considered positive.
Statistical analyses. All statistical analyses were performed by StatView version 5 software (SAS institute Inc, Cary, NC). Comparisons of the proportions between two populations utilized the χ 2 test. Comparisons of patient outcome (TTP and overall survival, OS) between patient groups utilized the Kaplan-Meier method and the log-rank test. All statistical tests were two-sided and P<0.05 was considered significant.
Results
Response to the gefitinib and patient outcome. The responses to gefitinib are summarized in Table II . The responders [complete response: CR + partial response: PR, (8/24) 33%] had significantly longer TTP and OS than non-responders (p<0.005 and p<0.05, respectively). In addition, the patients with controlled disease [CR + PR + stable disease: SD (13/24) 54%] had significantly longer TTP and OS (p<0.001 and p<0.001, respectively). We found no significant differences in the OS between patients with PR and SD nor could we prove that CR + PR better defined patients who benefited from the therapy than CR + PR + SD. We therefore performed the analyses based on the two groupings.
Analyses of the EGFR mutation status and staining of p-EGFR, p-Akt and E-cadherin.
We investigated the EGFR mutation status and the staining of p-EGFR, p-Akt and E-cadherin. We chose these proteins because they are intimately connected with the activity of EGFR and thus may predict responsiveness to gefitinib and/or patient outcome. In the mutation analysis, 10 patients were found to have an EGFR mutation: one had a point mutation L858R(T2573G), two had a deletion E746-A750del(2235-2249del), six had a deletion E746-A750del (2236-2250del), and one had a deletion L747-S752del, P753S(2240-2257del). All these mutations have been observed in gefitinib responders in the literature (2,3). Representative immunohistochemical staining is shown in Fig. 1 with the results summarized in Table III . The results of the EGFR mutation status are also shown. Positive p-Akt staining was associated with EGFR mutation, which is plausible because mutant EGFR stimulates the cell survival signal that is mediated by p-Akt. The staining intensity of p-EGFR and Ecadherin failed to show an association with the EGFR mutation and thus may be an independent parameter.
Predictors of the responsiveness to gefitinib. We then investigated the association between the expression of these proteins and the responsiveness to gefitinib (Table IV) . The presence of an EGFR mutation significantly associates with responsive diseases (CR + PR) or controlled diseases (CR + PR + SD). This is consistent with the results presented in previous reports (20) (21) (22) . We found no significant associations in the staining result for p-EGFR, p-Akt and E-cadherin.
Predictors of patient outcome. We compared the KaplanMeier curves to identify predictors of longer TTP and/or OS. As shown in Fig. 2A the positive staining of E-cadherin predicts a longer TTP (12.4 vs. 5.9 months, p<0.05) and longer OS (18.4 vs. 13.0 months, p<0.05). The presence of EGFR mutation(s) (p=0.13 and p=0.11, respectively, Fig. 2B ), as well as p-EGFR and p-Akt staining intensity failed to predict outcome. We then looked at the EGFR mutation status in conjunction with the E-cadherin staining intensity as predictors of these same parameters. As shown in Fig. 2C in the right panel, the patients with EGFR mutation-positive tumors and those with E-cadherin-positive tumors defined a patient group with a median OS of 18.4 months and excluded the patient group with the median OS of 3.7 months, although we failed to show a significant difference in TTP (Fig. 2C,  left panel) . Therefore, we consider that the patients with EGFR mutation-positive or E-cadherin-positive tumors are the most likely to benefit from gefitinib therapy.
Discussion
It was shown that NSCLC tumors with an EGFR mutation(s) respond to gefitinib at a rate of 65 to 100% (5) (6) (7) (20) (21) (22) (23) (24) . Several prospective phase II studies have shown that gefitinib therapy significantly lengthened TTP in NSCLC patients with EGFR mutation-positive tumors (5-7). Thus far, no prospective studies have reported on OS. Several retrospective studies have suggested that gefitinib therapy may result in a longer OS in patients with EGFR mutation-positive tumors (20, 21, 23) , however, we did not observe any significant differences in either TTP or OS. This is likely due to the size of the current study, as is discussed later.
We showed that positive E-cadherin staining is significantly associated with TTP and OS. Possible mechanisms that may explain this observation include that i) tumors with a lower E-cadherin expression progress faster than those with a higher expression and ii) E-cadherin modifies EGFR function and thus contributes to the effect of gefitinib treatment. The former mechanism is supported in reports that show that tumors with a positive E-cadherin staining are more frequent in early stage than in locally advanced or metastasizing NSCLCs (25) (26) (27) (28) . Similar results have been obtained in other malignancies such as the esophagus (29,30), stomach (31,32) , colon (33), ONCOLOGY REPORTS 19: 377-383, 2008 Table II. Response to gefitinib therapy. ------------------------------------------------- TTP, time to progression; OS, overall survival; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluated. (34) , pancreas (35) and urinary bladder (36, 37) . Moreover, in NSCLCs, a positive E-cadherin expression associates with a more differentiated histology (26, 28) and a better prognosis (25, 27, 28) . The latter mechanism is supported by reports showing that E-cadherin interacts with EGFR, thereby decreasing ligand-affinity (38, 39) and inhibiting activation (40) in several human tumor types including the esophageal, breast and lung (41) (42) (43) . Mechanisms i) and ii) stated above are not mutually exclusive and both may contribute to a better prognosis. Table III . EGFR mutation and staining of p-EGFR, p-Akt and E-cadherin. 
EGFR, epidermal growth factor receptor; p-EGFR, phosphorylated-EGFR; p-Akt, phosphorylated-Akt. Table IV . Gefitinib response summarized by the EGFR mutation status and by the staining of p-EGFR, p-Akt or E-cadherin. 
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EGFR, epidermal growth factor receptor; p-EGFR, phosphorylated-EGFR; p-Akt, phosphorylated-Akt.
- ---------------------------------------------------------------------------------------------------- The current study warrants a larger one and presents an important question. We have six panels in Fig. 2 , three of which showed significant differences and three of which did not. It is calculated that, if twice as many patients had been enrolled and had shown similar responsiveness and prognoses, all six sets of the two groups compared in Fig. 2 would have shown significant differences. To investigate this, a study should be scheduled where more than twice the number of patients is enrolled. We showed that tumors with a positive E-cadherin staining have a better prognosis after gefitinib therapy. It is, however, not clear whether the E-cadherin expression and EGFR mutation(s) contribute to it independently or synergistically. Basic and clinical researches addressing this issue may provide important information on the role of E-cadherin and EGFR in carcinogenesis.
